Predictors Of Treatment Outcomes Following Anti-vascular Endothelial Growth Factor (VEGF) Therapy For Neovascular AMD.
Funder
National Health and Medical Research Council
Funding Amount
$240,277.00
Summary
Age-related macular degeneration (AMD) is the most common cause of severe, irreversible loss of vision amongst elderly populations in the developed world. Bleeding in the retina destroys central vision. New treatments have been developed to stop this bleeding. However not all patients benefit equally, with some still losing vision. This project aims to investigate what determines how well an individual responds to treatment, in particular, how genes might influence the response.